Calcium channel blockers, specifically the short-acting form, appeared associated with increased risk for pancreatic cancer among postmenopausal women, according to a study presented at American Association for Cancer Research Annual Meeting.“Pancreatic cancer is not very common in the United States. It is the 12th most common cancer, but it is a very lethal cancer, as [it is] the third leading cause of cancer death in the U.S.” Zhensheng Wang, PhD, postdoctoral associate at Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, said during a press conference. Read more here . . .